Dihexa vs Semax: evidence, cost, and legality

Which is better, Dihexa or Semax?

Semax is graded human observational from Russian stroke studies without placebo control, which is weak but real human data. Dihexa is graded animal only, from one laboratory, with the HGF/c-Met mechanism paper retracted and the rat memory paper under an expression of concern, and no human safety data at all. On regulation, semax came off Category 2 and was recommended by PCAC for the 503A bulks list, while dihexa's nomination was withdrawn and it has no lawful compounding basis. [1] [2] [3] [4] [5] [6]

How do Dihexa and Semax compare?

Dihexa and Semax compared by dimension
Dimension	Dihexa	SemaxFavored
What it is [3] [7]	Synthetic oligopeptide derived from angiotensin IV (hexanoyl capped Tyr-Ile with an aminohexanoic amide tail).	Heptapeptide analog of ACTH fragment 4-10 with a stabilizing Pro-Gly-Pro tail.
Proposed mechanism [4] [7]	Reported to bind hepatocyte growth factor and potentiate c-Met signaling to drive synapse formation; the paper establishing this was retracted in 2025.	Raised hippocampal BDNF protein about 1.4 fold and trkB expression within hours of one intranasal dose in rats.
Human evidence [1] [2] [3] [8]	None. No human pharmacokinetic, safety, or efficacy study of any kind.	Open comparative Russian studies in acute ischemic stroke and chronic cerebrovascular insufficiency reporting faster recovery and fewer exacerbations; no blinding or placebo.
Data integrity [1] [3] [4]	Mechanism paper retracted (2025); design and rat memory paper under a 2021 expression of concern; no independent replication.	No retractions identified, but the clinical studies come from the developing research group and are published in Russian.
Theoretical safety concern [1] [9]	c-Met is an established oncogene, so potentiating it could plausibly promote tumor growth; no animal toxicology has been published.	Anxiety, irritability, insomnia, and nasal irritation reported; long term safety unknown.
Route [1] [3]	Oral or injected in rats; sold as capsules, powder, or transdermal products without absorption data.	Intranasal drops (Russian product and most sold forms).
FDA and compounding status [5] [6]	Nomination withdrawn, so no longer in Category 2, but not on the bulks list and not recommended by PCAC in July 2026; no lawful compounding basis.	Removed from 503A Category 2 on April 15, 2026; PCAC recommended the 503A bulks list in July 2026; no final rule yet. Registered prescription drug in Russia.
WADA status [10] [11]	Prohibited at all times under S0 (non-approved substances).	Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Dihexa and Semax: grade, status, and cost
Attribute	Dihexa	Semax
Class	Synthetic angiotensin IV derived oligopeptide (hexanoyl capped Tyr-Ile with an aminohexanoic amide tail), hepatocyte growth factor/c-Met potentiator	Synthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptide
What it is	Oral lab-made relative of the brain peptide angiotensin IV: rat memory data from one lab, a retracted mechanism paper, no human trials, no FDA approval.	Nasal peptide registered in Russia; rodent brain growth factor data and open label Russian stroke trials; not FDA approved; recommended for compounding in 2026.
Evidence	Evidence: Animal-only evidence	Evidence: Human observational evidence
FDA status	Regulatory: Removed from Category 2 (Apr 2026)	Regulatory: Under FDA review
Compounding	Dihexa has never been reviewed or approved by FDA for any use. It was named on the FDA 503A Category 2 list (substances with significant safety risks) in 2023. The FDA Category 2 page current as of April 22, 2026 now lists dihexa acetate under bulk drug substances nominated but withdrawn, so it is no longer in Category 2, but it is not on the 503A bulks list and was not among the peptides the Pharmacy Compounding Advisory Committee recommended on July 23 to 24, 2026. With no active nomination and no listing, a 503A pharmacy has no lawful basis to compound it. It is not eligible for 503B outsourcing and no licensed compounding pathway has been identified.	Semax was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023 and removed from it on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding semax to the 503A bulks list. As of the last verification date FDA has not published a final rule, so compounding pharmacies and state boards vary in whether they will fill it. It is not an FDA approved drug and is not eligible for 503B outsourcing. It is a registered prescription drug in Russia.
WADA	WADA: WADA prohibited	WADA: WADA status unclear
Routes	Oral (rat studies; sold as capsules or powder), Intraperitoneal injection (rat studies), Transdermal and subcutaneous products exist without absorption data	Intranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data)
Typical cost	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	No lawful compounded price: Semax is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 22, 2026	Sep 22, 2026

Has Dihexa been tested directly against Semax?

No published trial has compared Dihexa and Semax directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do Dihexa and Semax cost?

Typical cost of Dihexa and Semax
Dimension	Dihexa	Semax
Typical cost	Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	No lawful compounded price: Semax is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Price index in progress	Semax price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is dihexa stronger than semax?

There is no human evidence that dihexa does anything in people. Claims that it is far more potent than BDNF come from the inventing laboratory's rat and cell work, and the paper describing its mechanism was retracted in 2025. Semax has open label human stroke studies, though none were placebo controlled. [1] [3] [4]

Why was the dihexa paper retracted?

The 2014 journal article reporting that dihexa works through the HGF/c-Met system was retracted by the journal in April 2025, and the 2013 paper describing dihexa's design and rat memory effects carries a 2021 expression of concern. The mechanism should be treated as unconfirmed. [3] [4]

Can I get either one from a US pharmacy?

Semax may be available from some 503A pharmacies after the Pharmacy Compounding Advisory Committee recommended it for the bulks list in July 2026, depending on the state board. Dihexa has no lawful compounding basis: its nomination was withdrawn and it is not on the bulks list. [5] [6]

Does dihexa carry a cancer risk?

Possibly, in theory. Dihexa is proposed to boost signaling through c-Met, a receptor that drives several cancers and is the target of approved cancer drugs. No toxicology study in animals or safety study in humans has been published to test this. [3] [9]

Are they allowed in sport?

Dihexa is prohibited at all times under S0 as a non-approved substance. Semax is not named on the list, but S0 could apply, so tested athletes should confirm with their anti-doping organization. [10] [11]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Dihexa vs Semax: evidence, cost, and legality. https://peptideagent.ai/compare/dihexa-vs-semax
HTML link: <a href="https://peptideagent.ai/compare/dihexa-vs-semax">Dihexa vs Semax: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Dihexa vs Semax

The short answer